Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5
Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5
Chardan將Evelo Biosciences評級從買入下調至中性，將目標價從5美元下調至2.50美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間